Thromb Haemost 2011; 105(01): 161-168
DOI: 10.1160/TH10-07-0434
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model

Anne Godier
1   INSERM U765, Paris, France
2   Department of Anaesthesia and Critical Care, Paris Descartes University, Hôtel-Dieu Hospital, Paris, France
,
Marion Durand
3   Department of Thoracic Surgery, Nancy University Hospital, CHU, Nancy, France
4   INSERM U961, Nancy, France
,
Joseph Emmerich
1   INSERM U765, Paris, France
,
Blandine Dizier
1   INSERM U765, Paris, France
,
Thomas Lecompte
4   INSERM U961, Nancy, France
5   Laboratory of Haemostasis, Nancy University Hospital, CHU, Nancy, France
,
Charles-Marc Samama
1   INSERM U765, Paris, France
2   Department of Anaesthesia and Critical Care, Paris Descartes University, Hôtel-Dieu Hospital, Paris, France
› Author Affiliations
Further Information

Publication History

Received: 05 July 2010

Accepted after major revision: 08 September 2010

Publication Date:
22 November 2017 (online)

Zoom Image

Summary

As a potent anticoagulant agent, fondaparinux exposes a risk of bleeding. An effective way to reverse its effects is needed. It was the objective to study efficacy and safety of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of fondaparinux in a rabbit model of bleeding and thrombosis. In anaesthetised and ventilated rabbits, the Folts model was applied: a stenosis (75%) and an injury were carried out on the carotid artery, inducing thrombosis. Blood flow decreased as thrombus size increased until the pressure gradient was such that the thrombus was released and local blood flow was suddenly restored. This is known as a cyclic flow reduction (CFR). After the first CFR, rabbits were randomised into three groups: control (saline and saline after 1 minute), fondaparinux (fondaparinux [3 mg.kg−1] and saline), PCC (fondaparinux and PCC [40 UI.kg−1]). Then CFRs were recorded over 20 minutes. The following were measured: ear immersion bleeding time (BT), haemoglobin blood level (Hb1) and thrombelasto-metric parameters (ROTEM®). Finally, a hepatosplenic section was performed; 15 minutes later, the amount of blood loss was recorded as primary endpoint and Hb2 was measured. Blood loss was increased with fondaparinux and normalised with PCC. Regarding ROTEM® INTEM, fondaparinux increased clotting time and clotting formation time. PCC normalised these parameters. EXTEM and FIBTEM tests were not modified. Regarding safety, PCC did not increase CFRs. PCC reduced bleeding without increasing thrombosis and was effective to reverse the haemorrhagic effect of fondaparinux in this rabbit model.